SEARCH:   Advanced

Blood, 1 March 2008, Vol. 111, No. 5, pp. 2589-2596. Prepublished online as a Blood First Edition Paper on December 26, 2007; DOI 10.1182/blood-2007-09-112730. This Article Full Text Full Text (PDF) Supplemental Methods, Tables, and Figures All Versions of this Article: blood-2007-09-112730v1 111/5/2589    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Raponi, M. Articles by Karp, J. E. Search for Related Content PubMed PubMed Citation Articles by Raponi, M. Articles by Karp, J. E. Related Collections Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia Mitch Raponi1, Jeffrey E. Lancet2, Hongtao Fan3, Lesley Dossey1, Grace Lee1, Ivana Gojo4, Eric J. Feldman5, Jason Gotlib6, Lawrence E. Morris7, Peter L. Greenberg6, John J. Wright8, Jean-Luc Harousseau9, Bob Löwenberg10, Richard M. Stone11, Peter De Porre12, Yixin Wang1, and Judith E. Karp13 1 Veridex, La Jolla, CA; 2 H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa; 3 Centocor R&D, Malvern, PA; 4 Greenebaum Cancer Center, University of Maryland, Baltimore; 5 Weill Medical College, Cornell University, New York, NY; 6 Stanford Cancer Center, CA; 7 Blood and Bone Marrow Transplant Group of Georgia, Atlanta; 8 Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD; 9 Service d'Hematologie Clinique, Centre Hospitalier Universitaire (CHU) Hotel Dieu, Nantes, France; 10 Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands; 11 Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA; 12 Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium; and 13 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD At present, there is no method available to predict response to farnesyltransferase inhibitors (FTIs). We analyzed gene expression profiles from the bone marrow of patients from a phase 2 study of the FTI tipifarnib in older adults with previously untreated acute myeloid leukemia (AML). The RASGRP1/APTX gene expression ratio was found to predict response to tipifarnib with the greatest accuracy using a "leave one out" cross validation (LOOCV; 96%). RASGRP1 is a guanine nucleotide exchange factor that activates RAS, while APTX (aprataxin) is involved in DNA excision repair. The utility of this classifier for predicting response to tipifarnib was validated in an independent set of 58 samples from relapsed or refractory AML, with a negative predictive value (NPV) and positive predictive value (PPV) of 92% and 28%, respectively (odds ratio of 4.4). The classifier also predicted for improved overall survival (154 vs 56 days; P < .001), which was independent of other covariates, including a previously described prognostic gene expression classifier. Therefore, these data indicate that a 2-gene expression assay may have utility in categorizing a population of patients with AML who are more likely to respond to tipifarnib. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020